Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel).


themis_bioscience_logo

City: Vienna, Austria

Founded: 2009

Employees: 4

Financial Data: €10M Total Raised (as of 12/2015)

CEO: Erich Tauber

eric_tauber_themis

Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop vaccines for infants and adults from the preclinical to early clinical stages. It built its first successful vaccine on the Themaxyn platform: this replicating vector allows the plug-and-play insertion of virus antigen genes and their direct delivery to macrophages and dendritic cells in order to trigger an immune response.


Comment: Themis just announced that its Chikungunya vaccine candidate has begun Phase II clinical trials after raising €10M last year. Since expanding its ongoing partnership with Institut Pasteur in July, it is also developing a Zika vaccine that it plans to test in the clinic within a year.

Also, we love the Themis’ company logo!


Feature Image Credit: Labiotech Map

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.